1. Phyllanthin is widely used as hepatoprotective and antigenotoxic and inhibit function of P-gp.
1. Fraxetin has a marked inhibitory effect on S.aureus proliferation, it could disrupt nucleic acid and protein synthesis by preventing topoisomerase from binding to DNA.
2. Fraxetin shows antioxidant activity by inhibiting lipid peroxidation.
3. Fraxetin has dual-antioxidative functions, it has direct protective properties against low-density lipoprotein oxidation at lower concentrations, and higher concentrations of fraxetin induce antioxidant enzymes via Nrf2/ARE activation.
4. Fraxetin prevents rotenone-induced apoptosis by induction of endogenous glutathione in human neuroblastoma cells.
5. Fraxetin has antihyperglycemic effect on hepatic key enzymes of carbohydrate metabolism in streptozotocin-induced diabetic rats.
6. Fraxetin exhibits potent protective effects against CCl4 induced oxidative stress and hepatic fibrosis.
1. Tetrandrine can inhibit inward rectifying potassium current in cultured bovine aortic endothelial cells.
2. Tetrandrine exerts antifibrotic effects in both HSC-T6 cells and in rats with dimethylnitrosamine (DMN)-induced fibrosis.
3. Tetrandrine is an antitumor alkaloid, it arrests cells in G(1) by convergent mechanisms, including down-regulation of E2F1 and up-regulation of p53/p21(Cip1).
4. Tetrandrine shows anti-oxidant activity, anti-inflammatory and immunosuppressive activity.
5. Tetrandrine suppresses Wnt/β-catenin signaling transduction, the migration of DU145 and PC-3 cells, EOMA cell growth through the ROS/Akt pathway.
1. Astragaloside IV has been shown to protect the myocardium against ischemia/reperfusion injury, it also has beneficial effect in H/R-induced injury may be related to normalization of SR Ca2+ pump expression and, thus, it may prevent the depression in SR Ca2+ handling.
2. Astragaloside IV can reduce phosphorylation of JNK and ERK1/2 induced by complement membranous attack complex, the mechanism of Astragalus membranaceus in the treatment of membranous nephropathy (MN) may be related to its attenuation of podocyte injury through regulation of cytoskeleton and mitogen activated protein kinase.
3. Astragaloside IV can reduce blood pressure and triglyceride levels in fructose-fed rats and high dose of astragaloside IV also improves glucose tolerance and endothelium-dependent vasorelaxation, it may be useful in ameliorating food-induced metabolic syndrome.
4. Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF-кB signaling pathway in isoproterenol-induced myocardial hypertrophy, and attenuates Toll-like receptor 4 expression via NF-κB pathway under high glucose condition in mesenchymal stem cells.
5. Astragaloside IV can inhibit adenovirus replication and apoptosis in A549 cells in vitro.
6. Astragaloside IV has anti-fibrotic effect against systemic sclerosis.
1. Sophocarpine and matrine exert anti-cachectic effects probably through inhibition of TNF-alpha and IL-6 and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice.
2. Sophocarpine injection (called the Kangke injection) has been demonstrated to have significant antivirus effects against coxsackievirus B3 and therapeutic effects for viral myocarditis in clinical.
3. Sophocarpine exerts anti-inflammatory activity in vitro, and it may attribute to the inhibition of iNOS and COX-2 expressions via down-regulation of the JNK and p38 MAP kinase signal pathways and inhibition of NF-κB activation.
4. Sophocarpine can alleviate liver fibrosis mainly by inhibiting the TLR4 pathway, it may be a potential chemotherapeutic agent for chronic liver diseases.
5. Sophocarpine can ameliorate the ischemic injury induced by transient focal cerebral ischemia in rats and that this neuroprotective effect may be related to the anti-ASIC1 channel and anti-apoptotic action of sophocarpine.
6. Sophocarpine can alleviate hepatocyte steatosis and the potential mechanism may be the activated signaling pathway of AMPK.